Promising Outlook for CG Oncology: Strong Financial Health and Positive Trial Results for Cretostimogene

LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on CGON stock, giving a Buy rating today.

Sam Slutsky has given his Buy rating due to a combination of factors that highlight CG Oncology’s promising outlook. The company has recently reported strong financial health, with $688.4 million in cash reserves, which is expected to sustain operations until the first half of 2028, potentially leading to profitability. Furthermore, CG Oncology’s lead asset, cretostimogene, has shown favorable results in the pivotal BOND-003 trial for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), achieving a 46% complete response rate at 12 months without any severe treatment-related adverse events.
Additionally, cretostimogene’s performance compares well against its main competitor, TAR-200 by Johnson & Johnson, particularly in terms of tolerability. The rapid resolution of treatment emergent adverse events with cretostimogene, as opposed to TAR-200, further supports its potential market success. The company’s ongoing investigations into other bladder cancer settings, such as BCG-unresponsive papillary only disease, also demonstrate promising high-grade recurrence-free survival rates. These factors collectively contribute to a positive outlook for CG Oncology’s future growth and market presence.

In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $75.00 price target.